
    
      This is a randomized, placebo-controlled study in subjects with Pulmonary Arterial
      Hypertension (PAH) with an NYHA Class of III or IV who are receiving conventional therapy and
      bosentan. Subjects who fulfill the inclusion and exclusion criteria will be randomized to
      study drug (active or placebo) at a frequency of 6-9 inhalations per day for 12 weeks and
      will continue conventional therapy and bosentan. At the end of the double-blind phase study,
      open label Iloprost will be provided.
    
  